Synthetic Morphogens and Pro-morphogens for Aided Tissue Regeneration

Part of the Springer Series in Biomaterials Science and Engineering book series (SSBSE, volume 1)


Knowledge deriving from the biochemical signalling controlling tissue morphogenesis in embryonic and adult tissues offers the potential for the development of new therapeutic tools in regenerative medicine. To facilitate and control the cell-to-cell communication pathways, peptides and polymers can be synthesised that are capable of exposing to the damaged tissue either specific cell bioligands or functional groups able to bind bioactive molecules. These macromolecules would thus act as biomimetic pro-morphogens contributing to the generation of biochemical signalling gradients. In the first case, biomaterial scaffolds would be tethered with bioligands specifically encouraging the colonisation of “intermediate organisers” able to process morphogens/growth factors secreted by the “organiser” cells. In the second case, the exposure of functional groups of natural or synthetic origin able to capture endogenous morphogens could contribute to the establishment of biochemical gradients. Finally, in the clinical cases where tissue regeneration potential has significantly been comporomise, the use of these so-called synthetic pro-morphogens could be combined with that of specific peptidic growth factor analogues to generate ex novo completely synthetic gradients.


Vascular Endothelial Growth Factor Tissue Repair PAMAM Dendrimers Morphogen Gradient Biomaterial Scaffold 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kerszberg M, Wolpert L (1998) J Theor Biol 191:103–114CrossRefGoogle Scholar
  2. 2.
    Vincent JP, Briscoe J (2001) Morphogens. Curr Biol 11:R851–R854CrossRefGoogle Scholar
  3. 3.
    Kornberg TB, Guha A (2007) Understanding morphogen gradients: a problem of dispersion and containment. Curr Opin Genet Dev 17:264–271CrossRefGoogle Scholar
  4. 4.
    Wolpert L (2011) Positional information and patterning revisited. J Theor Biol 269:359–365CrossRefGoogle Scholar
  5. 5.
    Reddi A (1997) Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev 8(11):20Google Scholar
  6. 6.
    Pagès F, Kerridge S (2000) Trends Genet 16:40–44CrossRefGoogle Scholar
  7. 7.
    Yan D, Lin X (2009) Shaping morphogen gradients by proteoglycans. Cold Spring Harb Perspect Biol 1(3):a002493CrossRefGoogle Scholar
  8. 8.
    Ibanes M, Belmonte JCI (2008) Theoretical and experimental approaches to understand morphogen gradients. Mol Syst Biol 2008:176Google Scholar
  9. 9.
    Gregor T, Tank DW, Wieschaus EF, Bialek W (2007) Cell 130:153–164CrossRefGoogle Scholar
  10. 10.
    Kerszberg M (2004) Curr Opin Genet Dev 14:440–445CrossRefGoogle Scholar
  11. 11.
    Zhu AJ, Scott MP (2004) Genes Dev 18:2985–2997CrossRefGoogle Scholar
  12. 12.
    Lander AD, Nie Q, Wan FY (2002) Dev Cell 2:785–796CrossRefGoogle Scholar
  13. 13.
    Kerszberg M, Wolpert L (2007) Specifying positional information in the embryo: looking beyond morphogens. Cell 130:205–209CrossRefGoogle Scholar
  14. 14.
    Wolpert L, Jessell T, Lawrence P, Meyerowitz E, Robertson E, Smith J (2006) Principles of development, 3rd edn. Oxford University Press, New York, p 24Google Scholar
  15. 15.
    Green JBA, Smith JC (1991) Growth factors as morphogens. Trends Genet 7:245–250Google Scholar
  16. 16.
    Esteve P, Bovolenta P (2006) Secreted inducers in vertebrate eye development: more functions for old morphogens. Curr Opin Neurobiol 16:13–19CrossRefGoogle Scholar
  17. 17.
    Zou Y, Lyuksyutova AI (2007) Morphogens as conserved axon guidance cues. Curr Opin Neurobiol 17:22–28CrossRefGoogle Scholar
  18. 18.
    Santin M (2009) Towards high-performance and industrially-sustainable tissue engineering products (Chapter 16). In: Santin M (ed) Strategies in regenerative medicine: integrating biology with material science. Springer, New York, pp 467–493, ISBN-10: 0387746595, ISBN-13: 9780387746593Google Scholar
  19. 19.
    Hodde JP, Johnson CE (2007) Extracellular matrix as a strategy for treating chronic wounds. Am J Clin Dermatol 8:61–66CrossRefGoogle Scholar
  20. 20.
    Werner S, Krieg T, Smola H (2007) Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol 127:998–1008CrossRefGoogle Scholar
  21. 21.
    Li HH, Fu XB, Zhang L, Huang QJ, Wu ZG, Sun TZ (2008) Research of PDGF-BB gel on the wound healing of diabetic rats and its pharmacodynamics. J Surg Res 145:41–48CrossRefGoogle Scholar
  22. 22.
    Lee SH, Shin H (2007) Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv Rev 59:339–359CrossRefGoogle Scholar
  23. 23.
    Lal S, Barrow RE, Wolf SE, Chinkes DL, Hart DW, Heggers JP et al (2000) Biobrane improves wound healing in burned children without increased risk of infection. Shock 14:314–318CrossRefGoogle Scholar
  24. 24.
    Lukish JR, Eichelberger MR, Newman KD et al (2001) The use of bioactive skin substitute decreases length of stay for pediatric burn patients. J Pediatr Surg 36:1118–1121CrossRefGoogle Scholar
  25. 25.
    Unezaki S, Yoshii S, Mabuchi T, Saito A, Ito S (2009) Effects of neurotropic factors on nerve regeneration monitored by in vivo imaging in thy1-YFP transgenic mice. J Neoursci Methods 178:308–315CrossRefGoogle Scholar
  26. 26.
    Piquilloud G, Christen T, Pfister LA, Gander B, Papaloizos Y (2007) Variations in glial cell line-derived neurotrophic factor release from biodegradable nerve conduits modify the rate of functional motor recovery after rat primary nerve repairs. Eur J Neurosci 26:1109–1117CrossRefGoogle Scholar
  27. 27.
    Barras FM, Pasche P, Bouche N, Aebischer P, Zurn AD (2002) Glial cell line-derived neurotrophic factor released by synthetic guidance channels promotes facial nerve regeneration in the rat. J Neurosci Res 70:746–755CrossRefGoogle Scholar
  28. 28.
    Seeherman H, Wozney JM (2005) Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev 16:329–345CrossRefGoogle Scholar
  29. 29.
    Kelpke SS, Zinn KR, Rue LW, Thompson JA (2004) Site-specific delivery of acidic fibroblast growth factor stimulates angiogenic and osteogenic response in vivo. J Biomed Mater Res A 71A:316–325CrossRefGoogle Scholar
  30. 30.
    Mabilleau G, Aguado E, Stancu IC, Cincu C, Basle ME, Chappard D (2008) Effects of FGF-2 release from a hydrogel polymer on bone mass and microarchitecture. Biomaterials 29:1593–1600CrossRefGoogle Scholar
  31. 31.
    Schmoekel HG, Weber FE, Schense JC, Gratz KW, Schawalder P, Hubbell JA (2005) Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng 89(3):253–262CrossRefGoogle Scholar
  32. 32.
    Jeon O, Song SJ, Kang SW, Putnam AJ, Kim BS (2007) Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 28:2763–2771CrossRefGoogle Scholar
  33. 33.
    Molek P, Strukelj B, Bratkovic T (2011) Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 16:857–887CrossRefGoogle Scholar
  34. 34.
    Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317CrossRefGoogle Scholar
  35. 35.
    Smith GP, Petrenko VA (1997) Phage display. Chem Rev 97:391–410CrossRefGoogle Scholar
  36. 36.
    Ja WW, Roberts RW (2005) G-protein-directed ligand discovery with peptide combinatorial libraries. Trends Biochem Sci 20:318–324CrossRefGoogle Scholar
  37. 37.
    Tipps ME, Lawshe JE, Ellington AD, Mihic SJ (2010) Identification of novel specific allosteric modulators of the glycine receptor using phage display. J Biol Chem 285:22840–22845CrossRefGoogle Scholar
  38. 38.
    De Berardinis P, Haigwood N (2004) New recombinant vaccines based on the use of prokaryotic antigen-display systems. Expert Rev Vaccines 3:673CrossRefGoogle Scholar
  39. 39.
    Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295–304CrossRefGoogle Scholar
  40. 40.
    Hertveldt K, Belien T, Volckaert G (2009) General M13 phage display: M13 phage display in indentification and characterization of protein-protein interactions. Methods Mol Biol 502:321–339CrossRefGoogle Scholar
  41. 41.
    Sedlacek R, Chen E (2005) Screening for protease substrate by polyvalent phage display. Comb Chem High Throughput Screen 8:197–203CrossRefGoogle Scholar
  42. 42.
    Fernandez-Gacio A, Uguen M, Fastrez J (2003) Phage display as a tool for the directed evolution of enzymes. Trends Biotechnol 21:408–414CrossRefGoogle Scholar
  43. 43.
    Deller MC, Jones YE (2000) Cell surface receptors. Curr Opin Struct Biol 10:213–219CrossRefGoogle Scholar
  44. 44.
    Yamada N, Yanai R, Kawamoto K, Takashi Nagano T, Nakamura M, Inui M, Nishida T (2006) Promotion of corneal epithelial wound healing by a tetrapeptide (SSSR) derived from IGF-1. Invest Ophthalmol Vis Sci 47:3286–3292CrossRefGoogle Scholar
  45. 45.
    Brennand DM, Dennehy U, Ellis V, Scully MF, Tripathi P, Kakkar VV, Patel G (1997) Identification of a cyclic peptide inhibitor of platelet-derived growth factor-BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts. FEBS Lett 413:70–74CrossRefGoogle Scholar
  46. 46.
    Hardy B, Raiter A, Weiss C, Kaplan B, Tenenbaum A, Battler A (2007) Angiogenesis induced by novel peptides selected from a phage display library by screening human vascular endothelial cells under different physiological conditions. Peptides 28:691–701CrossRefGoogle Scholar
  47. 47.
    D’Andrea LD, Del Gatto A, Pedone C, Benedetti E (2006) Peptide-based molecules in angiogenesis. Chem Biol Drug Des 67:115–126CrossRefGoogle Scholar
  48. 48.
    Suzuki Y, Tanihara M, Suzuki K, Saitou A, Sufan W, Nishimura Y (2000) Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo. J Biomed Mater Res 50:405–409CrossRefGoogle Scholar
  49. 49.
    Horii A, Wang X, Gelain F, Zhang S (2007) Biological designer self-assembling peptide nanofibre scaffolds significantly enhance osteoblast proliferation, differentiation and 3-D migration. PLoS One 2(2):E190. doi: 10.1371/journal.pone.0000190 CrossRefGoogle Scholar
  50. 50.
    Simoes DCM, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C, Papapetropoulos A (2008) Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. Am J Respir Critic Care Med 177:1314–1321CrossRefGoogle Scholar
  51. 51.
    Smadja DM, Laurendeau I, Avignon C, Vidaud M, Aiach M, Gaussem P (2006) The angiopoietin pathway is modulated by PAR-1 activation on human endothelial progenitor cells. J Thromb Haemost 4:2051–2058CrossRefGoogle Scholar
  52. 52.
    Pollock JF, Healy KE (2009) Biomimetic and bioresponsive materials in regenerative medicine (Chapter 4). In: Santin M (ed) Strategies in regenerative medicine: integrating biology with material science. Springer, New York, pp 97–154, ISBN-10: 0387746595, ISBN-13: 9780387746593Google Scholar
  53. 53.
    Hern DL, Hubbell JA (1998) Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing. J Biomed Mater Res 39:266–276CrossRefGoogle Scholar
  54. 54.
    Schense JC, Hubbell JA (2000) Three-dimensional migration of neurites is mediated by adhesion site density and affinity. J Biol Chem 275:6813–6818CrossRefGoogle Scholar
  55. 55.
    Shin H, Jo S, Mikos AG (2002) Modulation of marrow stromal osteoblast adhesion on biomimetic oligo[poly(ethylene glycol) fumarate] hydrogels modified with Arg-Gly-Asp peptides and a poly(ethyleneglycol) spacer. J Biomed Mater Res 61:169–179CrossRefGoogle Scholar
  56. 56.
    Harbers GM, Healy KE (2005) The effect of ligand type and density on osteoblast adhesion, proliferation, and matrix mineralization. J Biomed Mater Res A 75:855–869Google Scholar
  57. 57.
    Brandley BK, Schnaar RL (1988) Covalent attachment of an Arg-Gly-Asp sequence peptide to derivatizable polyacrylamide surfaces: support of fibroblast adhesion and long-term growth. Anal Biochem 172:270–278CrossRefGoogle Scholar
  58. 58.
    Shin H, Zygourakis K, Farach-Carson MC et al (2004) Attachment, proliferation, and migration of marrow stromal osteoblasts cultured on biomimetic hydrogels modified with an osteopontin-derived peptide. Biomaterials 25:895–906CrossRefGoogle Scholar
  59. 59.
    Rezania A, Healy KE (1999) Biomimetic peptide surfaces that regulate adhesion, spreading, cytoskeletal organization, and mineralization of the matrix deposited by osteoblast-like cells. Biotechnol Prog 15:19–32CrossRefGoogle Scholar
  60. 60.
    Silva GA, Czeisler C, Niece KL et al (2004) Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303:1352–1355CrossRefGoogle Scholar
  61. 61.
    Schense JC, Bloch J, Aebischer P et al (2000) Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. Nat Biotechnol 18:415–419CrossRefGoogle Scholar
  62. 62.
    Nilsson F, Tarli L, Viti F, Neri D (2000) The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev 43:165–196CrossRefGoogle Scholar
  63. 63.
    Ivanenkov VV, Felici F, Menon AG (1999) Uptake and intracellular fate of phage display vectors in mammalian cells. Biochim Biophys Acta 1448:450–462CrossRefGoogle Scholar
  64. 64.
    Stacey A, Palasek ZJ, Cox ZJ, Collins JM (2007) Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis. J Pept Sci 13:143–148CrossRefGoogle Scholar
  65. 65.
    Skerra A (2000) Engineered protein scaffolds for molecular recognition. J Mol Recognit 13:167–187CrossRefGoogle Scholar
  66. 66.
    Wurch T, Lowe P, Caussanel V, Bes C, Beck A, Corvaia N (2008) Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation. Curr Pharm Biotechnol 9:502–509CrossRefGoogle Scholar
  67. 67.
    Duncan R, Izzo L (2005) Dendrimer biocompatibility and doxicity. Adv Drug Deliv Rev 57:2215–2237CrossRefGoogle Scholar
  68. 68.
    Esfand T (2001) Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 6:427–436CrossRefGoogle Scholar
  69. 69.
    Hobson LJ, Feast WJ (1999) Poly(amidoamine) hyperbranched systems: synthesis, structure and characterization. Polymer 40:1279–1297CrossRefGoogle Scholar
  70. 70.
    Wells NJ, Basso A, Bradley M (1999) Solid-phase dendrimer synthesis. Biopolymers 47:381–396CrossRefGoogle Scholar
  71. 71.
    Al Jamal KT, Ramaswamy C, Florence AT (2005) Supramolecular structures from dendrons and dendrimers. Adv Drug Deliv Rev 57:2238–2270CrossRefGoogle Scholar
  72. 72.
    Tang MX, Redemann CT, Szoka FC (1996) In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 7:703–714CrossRefGoogle Scholar
  73. 73.
    Monaghan S (2001) Solid-phase synthesis of peptide-dendrimer conjugates for an investigation of integrin binding. ARKIVOC 46–53Google Scholar
  74. 74.
    Wijelath E, Namekata M, Murray J, Furuyashiki M, Zhang S, Coan D, Wakao M, Harris RB, Suda Y, Wang LM (2010) Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J Cell Biochem 111:461–468CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Brighton Studies in Tissue-Mimicry and Aided Regeneration (BrightSTAR), School of Pharmacy and Biomolecular SciencesUniversity of BrightonBrightonUK

Personalised recommendations